Skip to content
ClinCalc Pro
Menu
Antiparasitic

Ivermectin

Brand names: Stromectol, Soolantra (topical)

Ivermectin is an antiparasitic agent used for onchocerciasis, strongyloidiasis and other helminthic and ectoparasitic infections, available in oral and topical formulations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds glutamate-gated chloride channels in invertebrate nerve and muscle cells, increasing chloride permeability and causing parasite paralysis and death.

Prescribing in practice

  • In areas co-endemic for Loa loa, treatment can precipitate serious or fatal encephalopathy in patients with high microfilarial loads, so screen before treating.
  • Onchocerciasis usually requires repeated dosing because the drug kills microfilariae but not adult worms.
  • The mammalian central nervous system is normally protected by the blood-brain barrier, but caution applies in conditions that may compromise it.

Monitoring

No routine laboratory monitoring is required; observe for Mazzotti-type reactions when treating microfilarial infections.

Counselling the patient

  • Itching, rash, swollen glands or joint aches can occur after treatment as parasites die.
  • Further doses may be needed to fully clear the infection.
  • Take oral ivermectin as directed and return for any planned repeat treatment.

Evidence & guidelines

Widely used in mass drug administration programmes for onchocerciasis; refer to the SPC and WHO guidance for indication-specific use.

Reference: NICE CKS; WHO; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.